-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Eltrombopag (EPAG) and romiplostim (ROM) are thrombopoietin receptor antagonists.
Prospective controlled studies have confirmed that they are effective against aplastic anemia (AA).
They were authorized to treat adults in Japan in 2017 and 2019, respectively Patients with aplastic anemia
.
However, to date, there is no data on the potential contribution of switching from ROM to EPAG or vice versa in terms of efficacy or tolerability
These 10 patients did not respond to the maximum dose of EPAG and then switched to ROM
.
All 10 patients received the maximum dose of ROM (20μg/kg/week)
immunity
In summary, although more patients and a longer follow-up period are needed to confirm the results of the study, the results of the study show the efficacy of ROM in patients with EPAG refractory AA
Original source:
Masataka Ise, et al.
Romiplostim is effective for eltrombopag-refractory aplastic anemia: results of a retrospective study in this message